23andMe Launches New Genetic Report on Osteoporosis
Provides 23andMe+ Premium members with insight into their likelihood of developing osteoporosis based on thousands of genetic variantsSUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe ...
23andMe has been quietly exploring a possible sale of its telehealth business, Lemonaid
The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...
23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...
Nature8d
What went wrong at 23andMe? Why the genetic-data giant risks collapse
At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.
23andMe announces continued concerns regarding liquidity
Me (ME) ended December 31, 2024 with cash and cash equivalents of $79.4M, compared to $126.6M as of September 30, 2024 and $216.5M as of ...
23andMe Board Explores Strategic Alternatives Amid Restructuring
23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...
Stocks to Watch: 23andMe, Manhattan Associates, Nextracker
Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...